Advanced Soft-tissue Sarcoma Clinical Trial
Official title:
A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma
This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone.
This is an open label phase 1b/2 study exploring the safety and efficacy of lurbinectedin with doxorubicin. - The phase 1b trial will follow a standard 3+3 design. Upon determination of the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lurbinectedin plus doxorubicin, the randomized phase 2 trial in participants with advanced leiomyosarcoma (LMS) will commence. Participants will be randomized 1:1 for enrollment to one of two treatment arms: - Arm 1: Lurbinectedin with Doxorubicin - Arm 2: Doxorubicin Monotherapy This is a Phase Ib/II clinical trial. A Phase Ib clinical trial tests the safety of an investigational drug combination and also tries to define the appropriate dose of the investigational drugs to use for further studies. "Investigational" means that the drugs are being studied. The U.S. Food and Drug Administration (FDA) has not approved lurbinectedin for this specific disease but it has been approved for the treatment of small cell lung cancer. The U.S. FDA has approved doxorubicin as a treatment option for soft-tissue sarcoma. Lurbinectedin is a synthetically derived chemical that binds to DNA. The binding to DNA likely induces cell death. Doxorubicin is a cytotoxic chemotherapy drug that kills cancer cells by several mechanisms including binding to DNA. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05043649 -
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
|
Phase 1 | |
| Recruiting |
NCT05146440 -
Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05620693 -
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
|
N/A | |
| Recruiting |
NCT05809830 -
Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06367075 -
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04874311 -
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05876715 -
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04757337 -
Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients
|
Phase 3 | |
| Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
| Terminated |
NCT05154630 -
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03022448 -
Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)
|
||
| Recruiting |
NCT04204941 -
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
|
Phase 3 | |
| Recruiting |
NCT05182164 -
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
|
Phase 2 | |
| Recruiting |
NCT05180695 -
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
|
Phase 1/Phase 2 | |
| Terminated |
NCT04780464 -
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
|
Phase 3 |